• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cosette Pharmaceuticals Appoints Vincent Colicchio as Senior Vice President of Operations

    2/10/25 8:00:00 AM ET
    $HLNE
    Investment Managers
    Finance
    Get the next $HLNE alert in real time by email

    Industry leader with 35+ years of experience in manufacturing operations and global supply chain excellence

    Cosette Pharmaceuticals, Inc., a leading specialty pharmaceuticals company, today announced the appointment of Vincent (Vin) Colicchio as Senior Vice President of Operations, effective February 3, 2025. In this role, Vin will lead Cosette's manufacturing, global supply chain, and operational strategy, ensuring efficiency, and supply continuity as the company continues its strong trajectory of growth and transformation.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210366017/en/

    Senior Vice President, Operations (Photo: Business Wire)

    Senior Vice President, Operations (Photo: Business Wire)

    "As we rapidly diversify our product portfolio and expand our footprint, we continue to enhance our operational capabilities" said Apurva Saraf, President and CEO, Cosette Pharmaceuticals. "Vin is an exceptional leader with deep expertise in leading complex operations with high-performing teams and driving efficiencies. His experience at large-scale U.S. manufacturing and global supply chain operations will play a critical role as we continue to advance our capabilities and expand our portfolio."

    Vin brings more than 35+ years of leadership in pharmaceutical manufacturing and supply chain operations, spanning semi-solids, liquids, oral solids, and transdermals in both branded and generic markets. Most recently, he served as Vice President of Supply Chain and External Manufacturing at Dr. Reddy's Laboratories, where he led end-to-end supply chain operations for North America, overseeing a network of more than 45 CMOs and CPOs across the US, Canada, and Europe. He played a key role in the acquisition and integration of Mayne Pharma's generics portfolio, strengthening Dr. Reddy's market position and operational efficiency.

    Prior to Dr. Reddy's, Vin held senior leadership roles at Amneal Pharmaceuticals, G&W Laboratories, GlaxoSmithKline, UCB Pharma, and Wyeth, where he successfully led manufacturing expansions, supply chain transformations, and operational optimization initiatives. His ability to streamline production, enhance supply resilience, and drive best-in-class manufacturing excellence has made him a recognized leader in the industry.

    "Cosette's dynamic growth and commitment to operational excellence make this an incredibly exciting opportunity," said Vin Colicchio, Senior Vice President, Operations. "I look forward to working alongside the talented teams at Cosette to scale our manufacturing capabilities, enhance supply chain agility, and to ensure seamless delivery of the highest quality medicines to the patients."

    Vin holds a B.S. in Biochemical Engineering from Rutgers University and an MBA in Management.

    About Cosette Pharmaceuticals:

    Cosette Pharmaceuticals, Inc. ("Cosette") is a US-based, fully integrated pharmaceutical company with a fast-growing portfolio of branded pharmaceuticals consisting of products in women's health, cardiology and dermatology. Cosette has a long history in quality manufacturing of complex dosage forms including topical creams, ointments, oral liquids/solutions and suppositories. Cosette has corporate and manufacturing facilities in New Jersey and North Carolina and is supported by 350+ dedicated team members across all functional areas. Cosette is backed by Avista Healthcare Partners, a healthcare focused private equity firm, and funds managed by Hamilton Lane, a private markets investment management firm (NASDAQ:HLNE). For more information, please visit www.cosettepharma.com and follow us on LinkedIn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250210366017/en/

    [email protected]

    Get the next $HLNE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HLNE

    DatePrice TargetRatingAnalyst
    5/15/2025Outperform → Perform
    Oppenheimer
    1/21/2025$186.00Perform → Outperform
    Oppenheimer
    1/6/2025$139.00Neutral → Sell
    Goldman
    9/12/2024$156.00Equal Weight
    Wells Fargo
    4/11/2024$115.00Overweight → Neutral
    JP Morgan
    1/11/2024Outperform → Perform
    Oppenheimer
    5/26/2023$87.00Perform → Outperform
    Oppenheimer
    3/15/2023$85.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $HLNE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Banner Capital Announces Fund I Recapitalization and Launch of Fund II

      SALT LAKE CITY, June 5, 2025 /PRNewswire/ -- Banner Capital Management, LLC ("Banner") is pleased to announce the closing of a portfolio recapitalization into Banner Capital Fund I ("Fund I") and the launch of Banner Capital Fund II ("Fund II").  Fund I Fund I is a multi-asset continuation fund with over $400 million in capital commitments, formed to acquire interests in eight of Banner's pre-fund portfolio companies. Funds managed by Hamilton Lane (NASDAQ:HLNE) acted as lead investor and many of Banner's pre-fund investors retained a meaningful interest in the portfolio compa

      6/5/25 12:45:00 PM ET
      $HLNE
      Investment Managers
      Finance
    • HAMILTON LANE INCORPORATED REPORTS STRONG FOURTH FISCAL QUARTER AND FISCAL YEAR 2025 RESULTS, WITH MANAGEMENT AND ADVISORY FEES GROWING BY 14% AND ASSETS UNDER MANAGEMENT GROWING BY 11% YEAR-OVER-YEAR

      CONSHOHOCKEN, Pa., May 29, 2025 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the fourth fiscal quarter and full fiscal year ended March 31, 2025. FISCAL YEAR 2025 HIGHLIGHTS Assets under management – Total assets under management of $138 billion grew 11% year-over-year. Fee-earning assets under management increased 10% to $72 billion over the same period.Revenue – Management and advisory fees increased 14% to $513.9 million for fiscal 2025.Carried Interest – Unrealized carried interest balance of $1.3 billion was up 3% year-over-year.Earnings per share – GAAP EPS of $5.41 on $217.4 million of GAAP net i

      5/29/25 7:08:00 AM ET
      $HLNE
      Investment Managers
      Finance
    • Classiq Raises $110M in Largest-Ever Quantum Software Funding Round

      TEL AVIV, Israel, May 12, 2025 (GLOBE NEWSWIRE) --  Classiq today announced raising $110 million in Series C funding, the largest ever for a quantum software company. The round was led by Entrée Capital, with participation from Norwest, NightDragon, funds managed by Hamilton Lane (NASDAQ:HLNE), Clal, Neva SGR, Phoenix, Team8, IN Venture, Wing, HSBC, Samsung Next and QBeat, as well as other new and existing investors. This investment brings Classiq's total funding to $173 million, positioning the company to meet growing demand by significantly scaling its go-to-market, customer success and R&D teams. Classiq will expand its global footprint to broaden its leading role in national quantum

      5/12/25 7:00:00 AM ET
      $HLNE
      Investment Managers
      Finance

    $HLNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider French River 5 Ltd claimed ownership of 480,015 shares and claimed ownership of 7 units of Class B Common Stock (SEC Form 3)

      3 - Hamilton Lane INC (0001433642) (Issuer)

      4/25/25 5:05:37 PM ET
      $HLNE
      Investment Managers
      Finance
    • Co-Chief Executive Officer Delgado-Moreira Juan was granted 34,031 shares, increasing direct ownership by 3% to 1,298,847 units (SEC Form 4)

      4 - Hamilton Lane INC (0001433642) (Issuer)

      3/18/25 5:00:47 PM ET
      $HLNE
      Investment Managers
      Finance
    • Co-Chief Executive Officer Hirsch Erik R. was granted 36,001 shares and covered exercise/tax liability with 3,386 shares, increasing direct ownership by 37% to 120,275 units (SEC Form 4)

      4 - Hamilton Lane INC (0001433642) (Issuer)

      3/18/25 4:58:27 PM ET
      $HLNE
      Investment Managers
      Finance

    $HLNE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Co-Chief Executive Officer Delgado-Moreira Juan bought $105,950 worth of shares (525 units at $201.81) (SEC Form 4)

      4 - Hamilton Lane INC (0001433642) (Issuer)

      11/13/24 4:31:06 PM ET
      $HLNE
      Investment Managers
      Finance

    $HLNE
    SEC Filings

    See more
    • SEC Form 10-K filed by Hamilton Lane Incorporated

      10-K - Hamilton Lane INC (0001433642) (Filer)

      5/30/25 4:12:58 PM ET
      $HLNE
      Investment Managers
      Finance
    • Hamilton Lane Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Hamilton Lane INC (0001433642) (Filer)

      5/29/25 6:59:39 AM ET
      $HLNE
      Investment Managers
      Finance
    • Amendment: SEC Form SCHEDULE 13D/A filed by Hamilton Lane Incorporated

      SCHEDULE 13D/A - Hamilton Lane INC (0001433642) (Subject)

      4/2/25 4:33:42 PM ET
      $HLNE
      Investment Managers
      Finance

    $HLNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Hamilton Lane downgraded by Oppenheimer

      Oppenheimer downgraded Hamilton Lane from Outperform to Perform

      5/15/25 8:08:14 AM ET
      $HLNE
      Investment Managers
      Finance
    • Hamilton Lane upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Hamilton Lane from Perform to Outperform and set a new price target of $186.00

      1/21/25 7:49:57 AM ET
      $HLNE
      Investment Managers
      Finance
    • Hamilton Lane downgraded by Goldman with a new price target

      Goldman downgraded Hamilton Lane from Neutral to Sell and set a new price target of $139.00

      1/6/25 8:11:18 AM ET
      $HLNE
      Investment Managers
      Finance

    $HLNE
    Leadership Updates

    Live Leadership Updates

    See more
    • Grenova Secures New Investment; Appoints Life Sciences Veteran to the Board

      Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova's board, and the successful completion of a new round of growth equity capital. These developments support Grenova's strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories worldwide. Ted Hull brings over 30 years of experience in the life sciences industry, including as a clinical lab CEO for the last 20+ years. In his role at Grenova, Mr. Hull is set to provide strategic leadership and to play a pivotal role in shaping the company's future. "I

      4/23/25 8:00:00 AM ET
      $HLNE
      Investment Managers
      Finance
    • Cosette Pharmaceuticals Appoints Vincent Colicchio as Senior Vice President of Operations

      Industry leader with 35+ years of experience in manufacturing operations and global supply chain excellence Cosette Pharmaceuticals, Inc., a leading specialty pharmaceuticals company, today announced the appointment of Vincent (Vin) Colicchio as Senior Vice President of Operations, effective February 3, 2025. In this role, Vin will lead Cosette's manufacturing, global supply chain, and operational strategy, ensuring efficiency, and supply continuity as the company continues its strong trajectory of growth and transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210366017/en/Senior Vice President, Operations (Photo

      2/10/25 8:00:00 AM ET
      $HLNE
      Investment Managers
      Finance
    • Cosette Pharmaceuticals Appoints Brad Leonard as Vice President, Generics Commercial Operation

      Experienced commercial leader joins Cosette to drive the next phase of growth and transformation Cosette Pharmaceuticals, Inc., a leading specialty pharmaceuticals company, today announced the appointment of Brad Leonard as Vice President, Generics Commercial Operations. In this role, Brad will spearhead Cosette's generics business, including Generics Sales, Marketing/Pricing, Customer Service, and Demand Planning, as the company continues its expansion in these markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250203104224/en/Brad Leonard, Vice President, Generics Commercial Operations (Photo: Business Wire) "Cosette is

      2/3/25 8:00:00 AM ET
      $HLNE
      Investment Managers
      Finance